Group 1 - The stock price of Fuxiang Pharmaceutical on August 27 was 10.05 yuan, down 0.59 yuan or 5.55% from the previous trading day [1] - The company primarily engages in the research, production, and sales of active pharmaceutical ingredients and intermediates for anti-infection drugs, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein [1] - Fuxiang Pharmaceutical is the largest supplier of sulbactam globally and the only domestic supplier in the sulbactam field certified by international standards [1] Group 2 - According to the company's 2025 semi-annual report, it achieved operating revenue of 515 million yuan in the first half of the year, a year-on-year decrease of 24.6%, with a net profit attributable to the parent company of -6.91 million yuan, an improvement from a loss of 22.46 million yuan in the same period last year [1] - In the lithium battery electrolyte additive business, the company has established an annual production capacity of 8,000 tons for VC products and 3,700 tons for FEC products [1] - The company has a production capacity of 1,200 tons per year in the microbial protein sector and is constructing a project with an annual capacity of 20,000 tons [1] Group 3 - On August 27, the net inflow of main funds into Fuxiang Pharmaceutical was 17.78 million yuan, accounting for 0.39% of the circulating market value; over the past five days, the cumulative net inflow was 20.96 million yuan, representing 0.46% of the circulating market value [2]

Core Viewpoint - The company has made significant progress in its strategic development, focusing on optimizing governance structures and enhancing operational efficiency while achieving a reduction in net losses during the first half of 2025 [5][6]. Company Overview - The company reported a revenue of 514.67 million yuan in the first half of 2025, with a net profit attributable to shareholders of -6.91 million yuan, reflecting a year-on-year reduction in losses by 15.55 million yuan [5][6]. Key Developments - The company has optimized its governance structure, ensuring continuity and stability through the re-election of the board and the appointment of senior management [6]. - The company’s new protein product successfully obtained GRAS certification in the U.S., facilitating its entry into international markets [6]. - The company was included in the first batch of the national bio-manufacturing landmark product list, showcasing its technological strength in the field of microbial protein [6]. Future Plans - For the second half of 2025, the company will focus on three main business divisions: pharmaceuticals, new energy, and synthetic biology, aiming to enhance marketing and R&D capabilities [7]. - The pharmaceutical division plans to deepen collaboration with key customers and enhance product development to improve market competitiveness [8]. - The new energy division aims to strengthen strategic partnerships and optimize production processes to reduce costs and enhance operational efficiency [8]. - The synthetic biology division will focus on commercializing its new protein product and expanding its market presence through innovative applications [9][10]. Product Development - The company is advancing its amino acid water-soluble fertilizer product, which utilizes by-products from its new protein production process, aiming for certification and market launch in the second half of 2025 [12].

Core Viewpoint - Jiangxi Fuxiang Pharmaceutical Co., Ltd. has reported on non-operating fund occupation and other related fund transactions for the first half of 2025, highlighting significant amounts involved in both non-operating and operating transactions [1]. Summary by Category Non-Operating Fund Occupation - The total amount of non-operating fund occupation as of June 2025 is reported to be 792,693,994.23 yuan, with a cumulative occurrence amount of 795,383,299.54 yuan [2]. - The company has identified various related parties, including controlling shareholders and subsidiaries, with significant balances in non-operating fund occupations [2]. Related Fund Transactions - The report details various related fund transactions, including amounts owed to and from subsidiaries, with a total of 714,353,787.84 yuan in outstanding balances as of June 2025 [2]. - Specific subsidiaries such as Jiangxi Xiangtai Life Science Co., Ltd. and Fuxiang (Shandong) New Materials Co., Ltd. have notable amounts in non-operating fund transactions, indicating a complex financial relationship within the group [2]. Operating Fund Transactions - The report also includes operating fund transactions, with various subsidiaries reporting accounts receivable and payable, indicating ongoing business activities [2]. - The total amount of operating fund transactions reflects the company's active engagement in its core business operations, with significant figures reported for accounts receivable across multiple subsidiaries [2].

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a decline in revenue for the first half of 2025, indicating challenges in its financial performance while showing improvements in net losses compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 515 million yuan, representing a year-on-year decrease of 24.58% [1] - The net loss attributable to shareholders of the listed company was 6.9112 million yuan, which narrowed by 69.23% year-on-year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 32.1798 million yuan, a reduction of 34.91% compared to the previous year [1] - The basic loss per share was 0.01 yuan [1]

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 515 million yuan, representing a year-on-year decrease of 24.58% [1] - The net profit attributable to shareholders of the listed company was -6.91 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -32.18 million yuan [1] - Basic earnings per share were -0.01 yuan [1]

证券代码：300497 证券简称：富祥药业 公告编号：2025-057 江西富祥药业股份有限公司 关于2025年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司2025年半年度报告全文及摘要将于2025年8月27日在 中国证监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露， 敬请投资者注意查阅。 特此公告。 江西富祥药业股份有限公司 2025 年 8 月 26 日 董事会 ...

江西富祥药业股份有限公司 2025 年半年度财务报告 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：江西富祥药业股份有限公司 单位：元 项目 期末余额 期初余额 流动资产： 货币资金 606,508,100.18 695,350,502.08 结算备付金 拆出资金 交易性金融资产 2,185,000.00 2,185,000.00 衍生金融资产 应收票据 27,664,255.58 42,783,498.32 应收账款 252,136,406.46 261,238,271.67 应收款项融资 165,605,297.04 194,141,196.88 预付款项 8,120,775.10 10,419,901.20 应收保费 应收分保账款 应收分保合同准备金 其他应收款 12,665,071.11 28,029,363.75 其中：应收利息 应收股利 买入返售金融资产 存货 471,593,590.60 421,053,194.07 其中：数据资源 合同资产 持有待售资产 一年内到期 ...

江西富祥药业股份有限公司 （一）实际募集资金金额、资金到位情况 截至 2025 年 6 月 30 日，公司本年度使用金额情况为： 经中国证券监督管理委员会出具的证监许可[2020]3231 号《关于同意江西富 祥药业股份有限公司向特定对象发行股票注册的批复》同意注册，本公司向特定 对象发行普通股（A 股）79,191,640.00 股，每股面值 1.00 元，发行价格 12.68 元 /股，共募集资金 1,004,149,995.20 元，扣除保荐承销发行费用人民币 10,000,000.00 元，扣除其他与发行权益性证券直接相关的外部费用 2,785,933.52 元，实际募集 资金净额为人民币 991,364,061.67 元。上述募集资金于 2020 年 12 月 31 日到位， 经立信会计师事务所（特殊普通合伙）验证，并由其出具信会师报字[2021]第 ZF10008 号验资报告，已存放于募集资金专户。公司对募集资金采取专户存储制 度，并与保荐机构、存放募集资金的开户银行签订了募集资金三方监管协议。 向特定对象发行股票募集资金使用情况对照表详见本报告附表 1。 （二）2025 年度募集资金使用情况及结 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-058 江西富祥药业股份有限公司（以下简称"公司"）第五届董事会第二次会议于 2025 年 8 月 15 日以电子邮件等方式通知全体董事，并于 2025 年 8 月 25 日以现场及通讯 的方式在景德镇市昌江区鱼丽工业区 2 号公司三楼会议室举行。 江西富祥药业股份有限公司 会议应出席董事 7 人，实际出席的董事 7 人，其中董事刘洪先生、陈祥强先生、 计小青女士以通讯表决方式出席会议。会议由董事长包建华主持，公司高管列席会议。 会议召开和表决程序符合《中华人民共和国公司法》等法律、法规及本公司章程的有 关规定，合法有效。 1、审议通过《2025 年半年度报告及其摘要》 第五届董事会第二次会议决议公告 二、董事会会议审议情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 经与会董事审议，通过如下决议： 一、董事会会议召开情况 特此公告。 江西富祥药业股份有限公司 董事会 2025 年 8 月 26 日 2、审议通过《关于 2025 年上半年度募集资金存放与使用情况的专项报告》 经审核，董事会认为 ...

生命•阳光•未来 二〇二五年八月 1 江西富祥药业股份有限公司 2025 年半年度报告全文 江西富祥药业股份有限公司 2025 年半年度报告 公告编号：2025－055 江西富祥药业股份有限公司 2025 年半年度报告全文 第一节重要提示、目录和释义 1、公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2、公司负责人包建华、主管会计工作负责人杨光及会计机构负责人(会计主管人员)谢 海燕声明：保证本半年度报告中财务报告的真实、准确、完整。 3、所有董事均已出席了审议本次半年报的董事会会议。 4、非标准审计意见提示 □适用√不适用 5、对半年度报告涉及未来计划等前瞻性陈述的风险提示 √适用□不适用 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司对任何投资 者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异。 6、本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素 是 药品生物制品业； 1）市场竞争风险 医药制造业方面，公司以化学合成酶抑制剂 ...